secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2026-06-29T12:30:43+00:00
Accession:  0001193125-26-286914
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos reports ALN1003 preclinical liver-weight finding after body-fat adjustment in DIO mouse study
--------------------------------------------------------------------------------

- 48-day DIO mouse study: ALN1003-treated animals had lower liver weight after adjusting for body fat (ANCOVA p=0.000005; HC3 robust p=0.000015).
- Liver-weight finding consistent with lower liver injury enzymes (ALT, AST, ALP) and lower mean NAS score (2.7 vs 5.0 for selected controls).
- HOMA-IR remained significant after adjusting for body fat (ANCOVA p=0.0006; HC3 p=0.0014).
- Favorable adipose biomarkers: lower leptin, higher adiponectin, higher adiponectin-to-leptin ratio in DIO Study 1.
- ALN1003 is non-hormonal, non-incretin small molecule; all data from non-GLP mouse studies, may not translate to humans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526286914/0001193125-26-286914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526286914/tcrt-20260629.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-286914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer